HPTN 083
2021
Cabotegravir for HIV Prevention in MSM and Transgender Women
In 4,566 cisgender MSM and transgender women at high risk of HIV, long-acting injectable cabotegravir every 8 weeks reduced HIV acquisition compared with daily oral TDF/FTC.
Result
Efficacy: Incident HIV infectionHR 0.34
Below 1 favours long-acting injectable cabotegravir every 8 weeks, above 1 favours daily oral TDF/FTC.
Event rates Long-acting injectable cabotegravir every 8 weeks 0.41 vs daily oral TDF/FTC 1.22 per 100 patient-years
Also reported: 66 % more effective.
- Subtopic
- Long-acting PrEP
- Design
- Double-blind, double-dummy RCT
- Relevance
- Important: one of several pillars.
- Source
- Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.doi 10.1056/NEJMoa2101016
Discussion & critique
Basis of the FDA approval of long-acting cabotegravir for PrEP, particularly impactful for populations with adherence challenges.